Better Therapeutics, Inc. · OTC:BTTX
Better Therapeutics — Investor Presentation (March 2024)
48 slides from Better Therapeutics's investor presentation, Mar 11, 2024
Slide 1: Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases
Exhibit 99.1 Pioneering Prescription Digital Therapeutics for Cardiometabolic Diseases March 2024 Property of Better Therapeutics, Inc. Not for distribution.
Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) is for informational purposes only. The information contained herein does not purport to be all-inclusive and neither Better Therapeutics, Inc. (“BetterTX” or the Company“) nor any of its respective affiliates nor any of its or their control persons, off
Slide 3: Our mission is to advance human health through behavior change
Our mission is to advance human health through the power of behavior change. Many of the most common (and costly) chronic diseases share lifestyle behaviors that contribute to disease progression. Better Therapeutics combines medical, behavioral and data sciences to develop clinically proven softwar
Slide 4: Better Therapeutics is poised to create the first multi-billion dollar PDT company
Better Therapeutics is poised to create the first, multi-billion dollar Prescription Digital Therapeutics company • Type 2 Diabetes is the most expensive chronic condition in the US ($400B+ annually) and its cost and prevalence continue to increase; despite advances in drug treatments, approximately
Slide 5: Leadership Team
LEADERSHIP TEAM Frank Karbe David Perry Mark Berman Jessica Meng Kristin Wynholds Chief Executive Co-Founder & Chief Medical Officer Chief Commercial Officer Chief Product Officer Officer Executive Chairman 5
Slide 6: Empowering people with type 2 diabetes
Empowering people with type 2 diabetes Clinically validated via a randomized controlled trial against established TM AspyreRx is the first cognitive clinical endpoint (A1c) behavioral therapy mobile app “Digital Only” treatment enables unique to receive FDA authorization to value proposition & rapid
Slide 7: Watch an AspyreRx product demo video
Watch an AspyreRx product demo video at www.AspyreRx.com
Slide 8: Contents: The Problem
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan NASDAQ Compliance 9
Slide 9: Chronic disease prevalence and healthcare spending
% % T 60 86 $ 4.1 of adults in the US of healthcare dollars are spent on US National Health 2 2 have a chronic disease 1 chronic disease maintenance Expenditure in 2020 Currently available drugs treat symptoms but do not impact the behaviors that contribute to disease progression. Most patients get
Slide 10: Diabetes is the most expensive chronic condition in the US
Diabetes is the most expensive chronic condition in the US and prevalence 1,2,3 continues to rapidly increase despite advances in pharmacotherapy Total US Healthcare Expenditures ($ in trillions) Americans Diagnosed with Diabetes (millions) 40 $4 40 Prevalence projected to increase 30 30 $3 % % 25 o
Slide 11: Cardiometabolic patients progress to more costly complications over time
The vast majority of patients diagnosed with cardiometabolic diseases progress in their disease, leading to more costly complications and interventions over time Example: Type 2 Diabetes Typical Disease Progression Additional Advanced Insulin Non-Insulin Pre-Diabetes Diagnosis Non-Insulin Comorbidit
Slide 12: Clinical guidelines highlight behavior change as foundation of treatment
Current clinical guidelines highlight behavior change as the foundation of treatment in type 2 diabetes CBT is considered the Gold Standard to help patients make lasting behavior changes by changing neural pathways in the brain Traditional CBT is also proven to be effective at addressing the behavio
Slide 13: Contents: Better Therapeutics Approach
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan NASDAQ Compliance 14
Slide 14: We combine medical, behavioral, and data sciences to develop software-based therapeutics
We combine medical, behavioral, and data sciences to develop clinically proven, software-based therapeutics targeting behavior change at scale Prescription Digital Therapeutics (PDTs) authorized by the FDA, prescribed by physicians and reimbursed via health insurance Focus on cardiometabolic disease
Slide 15: Competitive landscape
High Strength of Evidence Rx Behavioral Therapeutic COMPETITIVE LANDSCAPE TM AspyreRx is the first and only Regulatory Threshold CBT mobile app to receive FDA authorization to treat a metabolic disease Glucose Monitoring / Insulin Management It is also the only T2D treatment option delivered entirel
Slide 16: Our platform is grounded in behavioral theory
Our platform is grounded in behavioral theory and developed by experienced designers and engineers in collaboration with clinical experts • 8 years of design, testing, and iteration 6,244 • 6,244 patients participated in cohort studies, usability studies, and RCTs • Product evolution from human to s
Slide 17: Platform designed to be scalable across cardiometabolic diseases
Hypertension (High blood pressure) Our DTx platform is designed to be highly 70 million Type 2 Diabetes people suffering and rapidly scalable (High blood sugar) across large disease $30 billion 35 million people suffering Rx drug spending states because most cardiometabolic $52 billion Root Causes d
Slide 18: Pipeline of prescription digital therapeutics
We are advancing a pipeline of prescription digital therapeutics to treat multiple cardiometabolic diseases that share the same root causes Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Pivotal (BT-001) De Novo Submission & FDA Review Type 2
Slide 19: Contents: How our Product Works
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan NASDAQ Compliance 20
Slide 20: AspyreRx delivers CBT to treat T2D
AspyreRx delivers cognitive behavioral therapy to treat T2D by targeting the underlying behaviors at the root of disease progression in a proven, convenient, engaging digital app EVIDENCE BASED CONVENIENT & ENGAGING MECHANISM OF ACTION % • Fewer diabetes % 81 30 medications Patients using • Reduced
Slide 21: AspyreRx leverages CBT principles
AspyreRx leverages CBT principles to target thoughts and emotions that underlie a complex set of diabetes self-care behaviors Therapy Lessons help patients identify existing thoughts Solve Identify Helpful Therapy Problems and beliefs about their current diabetes self-care Ideas / Cope with Lessons
Slide 22: Supportive features enhance the CBT experience
Supportive features enhance Tracking & Progress the CBT experience Product Support • Tracking of key type 2 diabetes biometrics to show purposeful progress Therapy • Biometric notifications are in place for Lessons safety and tells patients when they need to talk to their doctor Skill • Nudges remin
Slide 23: Contents: Clinical Evidence
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan NASDAQ Compliance 24
Slide 24: AspyreRx pivotal study design
AspyreRx pivotal study was a randomized, controlled, open-label clinical trial designed to evaluate safety and effectiveness for type 2 diabetes after two 90-day treatment periods AspyreRx + Standard of Care Primary Endpoint Secondary Endpoint Day 90 Day 180 Participants with n = 325 Uncontrolled Ty
Slide 25: Diverse, nationally representative population enrolled
Broad eligibility criteria and decentralized recruitment ensured a nationally representative, diverse population enrolled across 6 U.S. States ~ 40% Zip Codes Represented Non-White 44% 56% Men Women ~ 30% Black 588 ~ 17% Latinx Without Median Household 98% Income College Degree Lived in low-income o
Slide 26: Pivotal study designed to test a real-world population
Control Intervention The AspyreRx pivotal study was No Glycemic Equipoise designed to test a real-world, difficult- to-treat population ++ ++ Key attributes allowing for imbalance of medication use: • Open-label A1c review at Day 90 and Day 180 Medications (+): Fixed throughout study • Study require
Slide 27: Statistically significant A1c reductions vs. Control
AspyreRx demonstrated clinically meaningful and statistically significant reductions in A1c of 0.4% vs. Control at 90 days 0.2 1.5x more SOC patients 0.1 increased medications prior AspyreRx continued 0.1 to Day 180 to provide statistically 0 significant reductions -0.1 in A1c of 0.3% vs. Primary En
Slide 28: Greater A1c reductions with 10 or more lessons
Greater A1c reductions were achieved by participants who completed 10 or more lessons in the first 90 days 0 -0.1 AspyreRx D90 n = 297 -0.2 D180 n = 244 -0.3 -0.3 -0.4 AspyreRx & ≥ 10 Lessons -0.4 -0.4 -0.5 D90 n = 137 D180 n = 122 -0.6 -0.6 -0.7 Baseline Day 90 Day 180 Healthcare providers should i
Slide 29: Meaningful Responders saw mean decrease of -1.3% HbA1c
Meaningful Responders saw a mean decrease of -1.3% HbA1c over 180 days* Meaningful Responders defined as > 0.4% A1c improvement and accounted for 50.4% of the AspyreRx group 14 12 MEDIAN MEAN -1.1% -1.3% 10 8 6 4 2 0 -0.4 -0.5 -0.6 -0.7 -0.8 -0.9 -1 -1.1 -1.2 -1.3 -1.4 -1.5 -1.6 -1.7 -1.8 -1.9 -2 -2
Slide 30: Reductions in fasting blood glucose through 180 days
AspyreRx demonstrated early and continued reductions in participants self-reported fasting blood glucose through 180 days* Day 90 0.0 -2.0 -2.7 -4.0 -6.0 -5.6 -5.9 -6.2 -8.0 -7.7 -7.7 -8.3 -8.4 -9.0 -9.1 -9.2 -10.0 -9.4 -10 -10.3 -10.6 -11 -11.2 -12.0 -11.6 -11.9 -12.0 -12.5 -13.2 -14.0 -15.0 -16.0
Slide 31: Improvements in systolic blood pressure and weight
In addition to A1c reductions, AspyreRx also demonstrated improvements in systolic blood pressure and weight Mean Change in Systolic Blood Pressure (mmHg) Mean Change in Body Weight (lbs) a b from Baseline to Day 180 from Baseline to Day 180 0 All Patients Baseline SBP > 139 mmHg -1 0 -2 -1.8 -1.9 -
Slide 32: Improvements in mood and quality of life
Statistically significant improvements in mood and quality of life (QoL) were also observed Improvements QoL Improvements in Mood PHQ-9 Change from Baseline at Day 180 SF-12 Physical Component Change from Baseline at Day 180 -0.2 0 0.2 0.4 0.6 0.8 0 0.5 1 1.5 2 2.5 3 3.5 4 AspyreRx -0.1 AspyreRx 3.7
Slide 33: Fewer adverse events and serious adverse events vs. Control
AspyreRx demonstrated statistically significant fewer adverse events and serious adverse events vs. Control AspyreRx Control a b Summary of AEs at 180 days P value n=325 n=343 Any treatment-emergent AE, n(%) 135 (41.5) 188 (54.8) <0.001 Treatment emergent AE possibly/probably related to study interv
Slide 34: Patient engagement exceeded app benchmarks
AspyreRx was developed to optimize the content and user experience to help keep patients engaged during their treatment These metrics exceeded the benchmarks for consumer health & wellness apps* 5.9 81% 61 Average minutes / day Patients using the NPS Score after spent in app app at 180 days 180 days
Slide 35: Pivotal Trial: Patient Feedback
Pivotal Trial: Patient Feedback “It works! It has kept me on track and aware. There “I have learned so much about myself and my poor is great information that is given. I love the lessons. eating habits. I am learning to love the new way of life Just love the app.” and want everyone suffering from d
Slide 36: AspyreRx becoming part of standard of care for adults with T2D
• Significant & growing unmet medical need • In-line with existing treatment guidelines We envision AspyreRx becoming part of the • Valuable at any stage in T2D disease progression standard of care for adults with T2D • Broadly accessible to anyone with a smartphone • Potential cost savings for paye
Slide 37: Breakthrough Device Designation for advanced liver disease (MASH)
We also received Breakthrough Device Designation from the FDA in February for our platform with the intent to treat advanced liver disease (MASH) STATISTICALLY SIGNIFICANT REDUCTION IN LIVER FAT REDUCTION IN MARKERS OF LIVER DAMAGE Change in ALT from Baseline Percent Change in MRI-PDFF Intent-to-Tre
Slide 38: Contents: Go-to-Market Plan
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan NASDAQ Compliance 39
Slide 39: Commercialization approach builds on scalability and broad access
Our commercialization approach builds on our core advantage of scalability and broad access to offer a high impact population health solution INITIAL FOCUS PAYERS POPULATION HEALTH PROVIDERS PATIENTS Gain coverage by showing Drive large scale adoption Position AspyreRx as Drive immediate engagement
Slide 40: Population Health: initial commercial priority
Population Health: Our initial commercial priority will be to create public & private population health partnerships at scale The “digital-only” aspect of our treatment approach enables rapid implementation, scalability and performance-based contracting opportunities that are unique to us. We expect
Slide 41: Population Health: alignment with Quintuple Aim goals
Population Health: AspyreRx’s unique value proposition fully aligned with the “Quintuple Aim” goals being adopted by most healthcare organizations The Quintuple Aim Goals for Healthcare Improvement Proven to improve universally accepted ● First & only fully digital FDA cleared app delivering CBT (go
Slide 42: Path to Growth
2026 Path to Growth Drive Broad Adoption • Convert institutional adoption to payer pay • Begin national HCP targeting to pull-through broad payer 2025 coverage Grow Traction • Launch targeted digital DTC to convert “ready to change” patients actively looking for solutions online • Continue to grow P
Slide 43: Payers perceive diabetes as highest-priority area for PDT
Diabetes 78% 20% Cardiovascular disease 56% 22% Asthma/COPD 49% 39% Payers perceive Obesity 37% 34% diabetes as the Oncology 37% 24% highest-priority area Depression/anxiety 56% 46% for managing PDT Opiod use 32% 46% disorder/addition products Pain management 24% 49% Smoking Cessation 17% 41% Stroke
Slide 44: Cost effectiveness analysis of pivotal study data
Based on our cost effectiveness analysis of our pivotal study data, AspyreRx leads to improvements for patients and may be less expensive for payers Cost Effectiveness Plane Initial Results: AspyreRx* Cost Cost Increasing Increasing New intervention Standard care more costly and dominates more effec
Slide 45: Glooko partnership accelerates AspyreRx adoption
Glooko Partnerships further CGMs accelerates AspyreRx adoption Pharmaceutical Drugs • Access to Glooko’s endocrinologist customers in 4,000+ clinics in the US • AspyreRx integration into Glooko platform increases awareness and educates HCPs on how to prescribe Other Connected • Glooko’s Precision En
Slide 46: List price and pricing model to ensure ROI
List Price for AspyreRx & Pricing Model to Ensure ROI • Expect most patients to be prescribed AspyreRx with one $750 refill for minimum 6-month treatment period WAC • AspyreRx has a predefined duration, offering cost predictability for payers per 90-day script • AspyreRx is competitively priced when
Slide 47: Contents: NASDAQ Compliance
The Problem Better Therapeutics Approach How our Product Works Contents Clinical Evidence Go-to-Market Plan Nasdaq Compliance 48
Slide 48: NASDAQ Compliance
NASDAQ Compliance • WereceivedadelistingnoticefromNASDAQonDecember13,2023 • WerequestedanappealwithaNASDAQpanelonDecember21,2023. Therequestforanappealwillstaythesuspensionanddelisting ofourcommonstockpendingthedecisionofthePanel • TheNASDAQhearingiscurrentlyscheduledforMarch14,2024 • Wehaveengageds
Better Therapeutics — Investor Presentation (March 2024) on 6ix